Utilidad del infliximab en el tratamiento de la amiloidosis secundaria en la enfermedad de Crohn
Infliximab in the treatment of amyloidosis secondary to Crohn¿s disease
Leído
16626
Vecesse ha leído el artículo
2534
Total PDF
14092
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 41 | 6 | 47 |
| 2025 5 | 120 | 77 | 197 |
| 2025 4 | 89 | 19 | 108 |
| 2025 3 | 130 | 49 | 179 |
| 2025 2 | 113 | 23 | 136 |
| 2025 1 | 112 | 21 | 133 |
| 2024 12 | 76 | 22 | 98 |
| 2024 11 | 67 | 43 | 110 |
| 2024 10 | 60 | 34 | 94 |
| 2024 9 | 78 | 22 | 100 |
| 2024 8 | 83 | 54 | 137 |
| 2024 7 | 87 | 28 | 115 |
| 2024 6 | 86 | 48 | 134 |
| 2024 5 | 118 | 39 | 157 |
| 2024 4 | 122 | 39 | 161 |
| 2024 3 | 71 | 25 | 96 |
| 2024 2 | 73 | 35 | 108 |
| 2024 1 | 76 | 26 | 102 |
| 2023 12 | 69 | 23 | 92 |
| 2023 11 | 87 | 27 | 114 |
| 2023 10 | 78 | 20 | 98 |
| 2023 9 | 91 | 36 | 127 |
| 2023 8 | 52 | 12 | 64 |
| 2023 7 | 85 | 19 | 104 |
| 2023 6 | 105 | 25 | 130 |
| 2023 5 | 89 | 30 | 119 |
| 2023 4 | 50 | 24 | 74 |
| 2023 3 | 72 | 22 | 94 |
| 2023 2 | 85 | 22 | 107 |
| 2022 1 | 97 | 24 | 121 |
| 2022 12 | 69 | 31 | 100 |
| 2022 11 | 67 | 29 | 96 |
| 2022 10 | 91 | 41 | 132 |
| 2022 9 | 53 | 38 | 91 |
| 2022 8 | 56 | 39 | 95 |
| 2022 7 | 81 | 42 | 123 |
| 2022 6 | 58 | 33 | 91 |
| 2022 5 | 61 | 29 | 90 |
| 2022 4 | 119 | 50 | 169 |
| 2022 3 | 70 | 56 | 126 |
| 2022 2 | 101 | 44 | 145 |
| 2021 1 | 80 | 28 | 108 |
| 2021 12 | 69 | 37 | 106 |
| 2021 11 | 61 | 42 | 103 |
| 2021 10 | 62 | 36 | 98 |
| 2021 9 | 79 | 33 | 112 |
| 2021 8 | 80 | 39 | 119 |
| 2021 7 | 76 | 30 | 106 |
| 2021 6 | 63 | 12 | 75 |
| 2021 5 | 93 | 38 | 131 |
| 2021 4 | 209 | 37 | 246 |
| 2021 3 | 145 | 33 | 178 |
| 2021 2 | 79 | 19 | 98 |
| 2020 1 | 97 | 20 | 117 |
| 2020 12 | 78 | 16 | 94 |
| 2020 11 | 53 | 19 | 72 |
| 2020 10 | 39 | 18 | 57 |
| 2020 9 | 51 | 15 | 66 |
| 2020 8 | 60 | 11 | 71 |
| 2020 7 | 56 | 7 | 63 |
| 2020 6 | 86 | 20 | 106 |
| 2020 5 | 62 | 12 | 74 |
| 2020 4 | 52 | 14 | 66 |
| 2020 3 | 48 | 14 | 62 |
| 2020 2 | 62 | 12 | 74 |
| 2020 1 | 66 | 18 | 84 |
| 2019 12 | 67 | 13 | 80 |
| 2019 11 | 77 | 19 | 96 |
| 2019 10 | 73 | 18 | 91 |
| 2019 9 | 53 | 27 | 80 |
| 2019 8 | 50 | 7 | 57 |
| 2019 7 | 75 | 18 | 93 |
| 2019 6 | 56 | 12 | 68 |
| 2019 5 | 62 | 14 | 76 |
| 2019 4 | 127 | 15 | 142 |
| 2019 3 | 72 | 34 | 106 |
| 2019 2 | 51 | 31 | 82 |
| 2019 1 | 41 | 19 | 60 |
| 2018 12 | 147 | 41 | 188 |
| 2018 11 | 174 | 24 | 198 |
| 2018 10 | 143 | 15 | 158 |
| 2018 9 | 115 | 31 | 146 |
| 2018 8 | 64 | 21 | 85 |
| 2018 7 | 61 | 14 | 75 |
| 2018 6 | 71 | 17 | 88 |
| 2018 5 | 70 | 16 | 86 |
| 2018 4 | 84 | 13 | 97 |
| 2018 3 | 89 | 10 | 99 |
| 2018 2 | 97 | 5 | 102 |
| 2018 1 | 108 | 12 | 120 |
| 2017 12 | 98 | 14 | 112 |
| 2017 11 | 82 | 13 | 95 |
| 2017 10 | 77 | 9 | 86 |
| 2017 9 | 59 | 13 | 72 |
| 2017 8 | 76 | 9 | 85 |
| 2017 7 | 78 | 11 | 89 |
| 2017 6 | 82 | 15 | 97 |
| 2017 5 | 103 | 13 | 116 |
| 2017 4 | 67 | 10 | 77 |
| 2017 3 | 69 | 7 | 76 |
| 2017 2 | 77 | 9 | 86 |
| 2016 1 | 55 | 4 | 59 |
| 2016 12 | 117 | 8 | 125 |
| 2016 11 | 135 | 10 | 145 |
| 2016 10 | 195 | 21 | 216 |
| 2016 9 | 236 | 4 | 240 |
| 2016 8 | 308 | 5 | 313 |
| 2016 7 | 262 | 7 | 269 |
| 2016 6 | 167 | 0 | 167 |
| 2016 5 | 190 | 0 | 190 |
| 2016 4 | 142 | 0 | 142 |
| 2016 3 | 161 | 0 | 161 |
| 2016 2 | 162 | 0 | 162 |
| 2015 1 | 193 | 0 | 193 |
| 2015 12 | 214 | 0 | 214 |
| 2015 11 | 174 | 0 | 174 |
| 2015 10 | 172 | 0 | 172 |
| 2015 9 | 138 | 0 | 138 |
| 2015 8 | 124 | 0 | 124 |
| 2015 7 | 150 | 0 | 150 |
| 2015 6 | 76 | 0 | 76 |
| 2015 5 | 141 | 0 | 141 |
| 2015 4 | 41 | 0 | 41 |
| 2015 2 | 2350 | 0 | 2350 |
Mostrar todo
